FDA Accepts Supplement for Inavolisib by Genentech
The FDA has accepted a supplemental NDA for Inavolisib submitted by Genentech.
Therapeutic Area
Therapeutic area intelligence for PI3K Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.